3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neoplasms
3
Fallopian Tube Neoplasms
3
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Castration Resistant Prostate Cancer
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia
1
Leiomyosarcoma
1
Glioblastoma
1
Colorectal Neoplasms
1
Adenocarcinoma of the Oesophagus
1
ATM Gene Mutation
1
Interventions
Cisplatin
15
Pemetrexed
12
pembrolizumab
9
Carboplatin
8
Nivolumab
7
Cyclophosphamide
6
Platinum
5
Ipilimumab
5
1,2-diaminocyclohexaneplatinum II citrate
5
fludarabine
3
Radiotherapy, Intensity-Modulated
3
Interleukin-2
3
Gemcitabine
3
tremelimumab
2
durvalumab
2
atezolizumab
2
aldesleukin
2
Radiotherapy
2
Radiation
2
Photochemotherapy
2
Pharmaceutical Preparations
2
Methotrexate
2
Drug Therapy
2
Chemotherapy, Adjuvant
2
Cerebral Decortication
2
nintedanib
1
methoxyamine
1
decitabine and cedazuridine drug combination
1
cemiplimab
1
cediranib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
rucaparib
×
1 year
×
Clear all
No trials found.